Literature DB >> 15384974

The expression of P-glycoprotein in AML cells with FLT3 internal tandem duplications is associated with reduced apoptosis in response to FLT3 inhibitors.

Hannah M Hunter1, Monica Pallis, Claire H Seedhouse, Martin Grundy, Claire Gray, Nigel H Russell.   

Abstract

P-glycoprotein (pgp), a membrane efflux pump, is recognized to have an anti-apoptotic function. Internal tandem duplications (ITDs) of the Fms-like tyrosine kinase 3 (FLT3) receptor are the most common mutations in acute myeloid leukaemia (AML). Both ITDs and pgp positivity confer an adverse clinical prognosis. FLT3 inhibitors induce variable apoptosis in cell lines transfected with FLT3 ITDs. We studied the effect of herbimycin A, AG1296 and PKC412 on primary AML blasts. All compounds showed significantly higher cell kill after 48-h incubation in samples with an ITD compared with wild type (Herbimicin P < 0.001; AG1296 P = 0.001, PKC412, P = 0.002). Pgp-positive samples were significantly less sensitive to herbimycin and AG1296 than pgp-negative samples, although neither molecule inhibited the efflux function of pgp. The concurrent incubation with the pgp inhibitor PSC833 resulted in an enhanced cell kill in 4/5 ITD pgp-positive samples versus two of nine ITD pgp-negative samples. PKC412 inhibited pgp function and induced cell death in FLT3 ITD/pgp-positive samples. We conclude that AML samples with a FLT3 ITD are more susceptible to these inhibitors than wild-type samples. However, the expression of pgp in cells with FLT3 ITDs can reduce their sensitivity to FLT3 inhibitors and therefore pgp expression should be assessed in clinical trials of FLT3 inhibitors. Copyright 2004 Blackwell Publishing Ltd

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15384974     DOI: 10.1111/j.1365-2141.2004.05145.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  12 in total

1.  The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2.

Authors:  Rupashree Sen; Karthika Natarajan; Jasjeet Bhullar; Suneet Shukla; Hong-Bin Fang; Ling Cai; Zhe-Sheng Chen; Suresh V Ambudkar; Maria R Baer
Journal:  Mol Cancer Ther       Date:  2012-07-09       Impact factor: 6.261

2.  The FLT3 inhibitor midostaurin selectively resensitizes ABCB1-overexpressing multidrug-resistant cancer cells to conventional chemotherapeutic agents.

Authors:  Sung-Han Hsiao; Sabrina Lusvarghi; Yang-Hui Huang; Suresh V Ambudkar; Sheng-Chieh Hsu; Chung-Pu Wu
Journal:  Cancer Lett       Date:  2019-01-11       Impact factor: 8.679

3.  Synergistic effect of arsenic trioxide and flt3 inhibition on cells with flt3 internal tandem duplication.

Authors:  Shinichiro Takahashi; Hideo Harigae; Hisayuki Yokoyama; Izumi Ishikawa; Shouri Abe; Masue Imaizumi; Takeshi Sasaki; Mitsuo Kaku
Journal:  Int J Hematol       Date:  2006-10       Impact factor: 2.490

4.  Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors.

Authors:  Mark Levis; Patrick Brown; B Douglas Smith; Adam Stine; Rosalyn Pham; Richard Stone; Daniel Deangelo; Ilene Galinsky; Frank Giles; Elihu Estey; Hagop Kantarjian; Pamela Cohen; Yanfeng Wang; Johannes Roesel; Judith E Karp; Donald Small
Journal:  Blood       Date:  2006-07-20       Impact factor: 22.113

5.  The FLT3 and PDGFR inhibitor crenolanib is a substrate of the multidrug resistance protein ABCB1 but does not inhibit transport function at pharmacologically relevant concentrations.

Authors:  Trevor J Mathias; Karthika Natarajan; Suneet Shukla; Kshama A Doshi; Zeba N Singh; Suresh V Ambudkar; Maria R Baer
Journal:  Invest New Drugs       Date:  2015-01-20       Impact factor: 3.850

Review 6.  FLT3 inhibitors for acute myeloid leukemia: successes, defeats, and emerging paradigms.

Authors:  Baku Acharya; Debasmita Saha; Daniel Armstrong; Naga Rajiv Lakkaniga; Brendan Frett
Journal:  RSC Med Chem       Date:  2022-05-23

Review 7.  Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens.

Authors:  Keith Pratz; Mark Levis
Journal:  Leuk Lymphoma       Date:  2008-05

8.  The Pim kinase inhibitor SGI-1776 decreases cell surface expression of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and drug transport by Pim-1-dependent and -independent mechanisms.

Authors:  Karthika Natarajan; Jasjeet Bhullar; Suneet Shukla; Mehmet Burcu; Zhe-Sheng Chen; Suresh V Ambudkar; Maria R Baer
Journal:  Biochem Pharmacol       Date:  2012-12-19       Impact factor: 5.858

9.  P-glycoprotein and breast cancer resistance protein in acute myeloid leukaemia cells treated with the aurora-B kinase inhibitor barasertib-hQPA.

Authors:  Martin Grundy; Claire Seedhouse; Nigel H Russell; Monica Pallis
Journal:  BMC Cancer       Date:  2011-06-16       Impact factor: 4.430

10.  The FLT3 inhibitor quizartinib inhibits ABCG2 at pharmacologically relevant concentrations, with implications for both chemosensitization and adverse drug interactions.

Authors:  Jasjeet Bhullar; Karthika Natarajan; Suneet Shukla; Trevor J Mathias; Mariola Sadowska; Suresh V Ambudkar; Maria R Baer
Journal:  PLoS One       Date:  2013-08-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.